The role of aberrant DNA methylation in cancer initiation and clinical impacts
- Author(s)
- Geissler, F; Nesic, K; Kondrashova, O; Dobrovic, A; Swisher, EM; Scott, CL; Wakefield, JM;
- Journal Title
- Therapeutic Advances in Medical Oncology
- Abstract
- Epigenetic alterations, including aberrant DNA methylation, are now recognized as bone fide hallmarks of cancer, which can contribute to cancer initiation, progression, therapy responses and therapy resistance. Methylation of gene promoters can have a range of impacts on cancer risk, clinical stratification and therapeutic outcomes. We provide several important examples of genes, which can be silenced or activated by promoter methylation and highlight their clinical implications. These include the mismatch DNA repair genes MLH1 and MSH2, homologous recombination DNA repair genes BRCA1 and RAD51C, the TERT oncogene and genes within the P15/P16/RB1/E2F tumour suppressor axis. We also discuss how these methylation changes might occur in the first place - whether in the context of the CpG island methylator phenotype or constitutional DNA methylation. The choice of assay used to measure methylation can have a significant impact on interpretation of methylation states, and some examples where this can influence clinical decision-making are presented. Aberrant DNA methylation patterns in circulating tumour DNA (ctDNA) are also showing great promise in the context of non-invasive cancer detection and monitoring using liquid biopsies; however, caution must be taken in interpreting these results in cases where constitutional methylation may be present. Thus, this review aims to provide researchers and clinicians with a comprehensive summary of this broad, but important subject, illustrating the potentials and pitfalls of assessing aberrant DNA methylation in cancer.; Silencing genes role in initiation of cancer and clinical impacts Genes can be silenced by molecular tags being placed on them. This is a normal process that controls when and where genes are available to be used. In some cases this silencing can be incorrectly applied to genes involved in preventing cancer, causing cancer initiation and progression. This review discusses the role of one of these tagging processes, DNA methylation and its role in initiation of cancer and implications for treatment.; eng
- Publisher
- Sage
- Keywords
- BRCA-related cancers; diagnosis; epigenomics; genomic testing; genomics; homologous recombination deficiency; oncogenic driver mutations; targeted therapy; therapeutic resistance
- Research Division(s)
- Bioinformatics; Cancer Biology And Stem Cells
- PubMed ID
- 38293277
- Publisher's Version
- https://doi.org/10.1177/17588359231220511
- Open Access at Publisher's Site
https://doi.org/10.1177/17588359231220511- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-02-29 09:01:56
Last Modified: 2024-02-29 09:12:04